Bedrijfsoverzicht
AbbVie Inc. is a research-based biopharmaceutical company that engages globally in the research and development, manufacturing, commercializing, and sale of medicines and therapies. The enterprise operates within the healthcare sector, specifically classified under the industry of drug manufacturers-general, positioning it as a key player in the pharmaceutical supply chain. As of the latest data, the company holds a substantial market capitalization of $367.80 billion, while generating annual revenue of $61.16 billion and employing a workforce of 57,000 individuals. These valuation and revenue figures indicate that AbbVie commands a significant position within the global biopharmaceutical landscape, reflecting the high capital intensity and large-scale operational footprint typical of major drug manufacturers. The scale of the company, evidenced by its massive employee count and multi-billion dollar revenue stream, underscores its capacity to invest heavily in R&D pipelines and maintain extensive distribution networks for products such as Skyrizi, Rinvoq, and Imbruvica.
Financiële gezondheid
The company reported a total revenue of $61.16 billion over the trailing twelve months, with a net income of $4.19 billion and an EBITDA of $29.25 billion. The substantial gap between the $61.16 billion in revenue and the $4.19 billion in net income reveals a cost structure that includes significant operating expenses, research costs, and tax obligations, yet still maintains a robust profitability profile. AbbVie generates $18.34 billion in free cash flow, which provides the organization with considerable financial flexibility to fund ongoing research projects, manage debt obligations, and pursue strategic acquisitions without relying heavily on external financing. The company's gross margin stands at 71.6%, indicating a high pricing power and efficient production process typical of branded pharmaceutical products, while the operating margin of 34.1% reflects strong control over administrative and selling expenses. Furthermore, the profit margin of 6.9% demonstrates the final efficiency of converting sales into actual profit after all costs, including taxes and interest, have been accounted for. In terms of leverage, the company holds $5.26 billion in cash against $68.40 billion in debt, resulting in a debt-to-equity ratio that is listed as N/A, suggesting a capital structure heavily reliant on equity or complex debt instruments rather than standard leverage metrics. The current ratio of 0.67 indicates that the company's current assets are less than its current liabilities, which may suggest a reliance on long-term financing or specific asset liquidation strategies to meet short-term obligations. Return on Equity is reported at an exceptionally high 6225.0%, while Return on Assets sits at 9.8%, metrics that reveal the management's effectiveness in generating substantial returns relative to the capital invested, though the ROE figure warrants scrutiny given the company's specific capitalization structure.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is 87.74, whereas the forward P/E is significantly lower at 12.92, implying that the market expects a substantial increase in earnings growth or that the current earnings base includes non-recurring items that will not persist in future valuations. The price-to-book ratio is -112.40, a negative figure that typically indicates the book value per share is negative due to accumulated losses or specific accounting treatments, rendering the traditional premium over book value metric less applicable for standard comparison. Additionally, the price-to-sales ratio of 6.01 and an EV/EBITDA of 14.73 suggest that the market is willing to pay a premium for the company's sales and earnings power relative to its enterprise value, reflecting confidence in future cash generation capabilities. Regarding price action, the stock has traded between a 52-week low of $168.54 and a 52-week high of $244.81, providing a historical range against which current trading levels can be contextualized. The beta value of 0.36 indicates that the stock exhibits low volatility relative to the broader market, moving significantly less than the overall index and offering a more stable price trajectory in comparison to highly volatile biotech or small-cap equities.
Growth & Income
AbbVie has demonstrated a revenue growth rate of 10.0% year-over-year, while the earnings growth rate is listed as N/A, preventing a direct calculation of the spread between revenue and earnings expansion but highlighting the importance of margin expansion or one-time factors in driving profit performance. As a dividend payer, the company offers a yield of 3.3%, supported by a payout ratio of 276.8%, which indicates that the dividends paid exceed the reported net income, a situation often funded by cash flows or the reduction of accumulated losses rather than current-year profits alone. Given the payout ratio exceeds 100%, the sustainability of these dividends relies heavily on the robust free cash flow generation of $18.34 billion rather than a reliance on current net income. The overall growth and income profile presents a scenario of steady top-line expansion accompanied by a high-yield dividend, balancing capital returns to shareholders with continued investment in the company's therapeutic areas.